CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer

Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients develop resistance or never respond. We find that the transcription factor CREB5 confers enzalutamide resistance in an open readi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Justin H., Seo, Ji-Heui, Beshiri, Michael L., Wankowicz, Stephanie, Liu, David, Cheung, Alexander, Li, Ji, Qiu, Xintao, Hong, Andrew L., Botta, Ginevra, Golumb, Lior, Richter, Camden, So, Jonathan, Sandoval, Gabriel J., Giacomelli, Andrew O., Ly, Seav Huong, Han, Celine, Dai, Chao, Pakula, Hubert, Sheahan, Anjali, Piccioni, Federica, Gjoerup, Ole, Loda, Massimo, Sowalsky, Adam G., Ellis, Leigh, Long, Henry, Root, David E., Kelly, Kathleen, Van Allen, Eliezer M., Freedman, Matthew L., Choudhury, Atish D., Hahn, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886683/
https://www.ncbi.nlm.nih.gov/pubmed/31747605
http://dx.doi.org/10.1016/j.celrep.2019.10.068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886683/
https://www.ncbi.nlm.nih.gov/pubmed/31747605
http://dx.doi.org/10.1016/j.celrep.2019.10.068

Ejemplares similares